All In Biotech

Drug Trial Radar · NCT06141486

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 943 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

943

Actual

Start

Dec 27, 2023

Primary completion

Mar 24, 2028

Study completion Mar 24, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This event-driven study will end when the target number of 6-month cCDP events is achieved, and the study is expected to last 43 months from randomization of the first participant to the common study end. * The number of scheduled visits will be up to 25 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months. * If the prespecified number of events for 6-month cCDP is not reached by V21/W180, scheduled visits will continue every 3 months.

Conditions

  • Multiple Sclerosis

Interventions

  • FrexalimabDrug

    SAR441344 Solution for IV infusion

  • PlaceboDrug

    Solution for IV infusion

  • MRI contrast-enhancing agentsDrug

    IV, as per respective label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to onset of composite confirmed disability progression (cCDP) confirmed over 6 months in the double-blind treatment periodTime frame: Up to 36 months

Locations

311 sites in 27 countries. Site status is shown where the registry gives one.

  • Alabama Neurology Associates- Site Number : 8400115

    Homewood, Alabama

  • Perseverance Research Center- Site Number : 8400138

    Scottsdale, Arizona

  • Imaging Endpoints- Site Number : 8400050

    Scottsdale, Arizona

  • Sutter East Bay Medical Foundation - Berkeley- Site Number : 8400134

    Berkeley, California

  • University of California Irvine - School of Medicine- Site Number : 8400143

    Irvine, California

  • University of California San Diego - La Jolla- Site Number : 8400095

    La Jolla, California

  • Kaiser Permanente - Los Angeles Medical Center- Site Number : 8400184

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian- Site Number : 8400031

    Newport Beach, California

  • Stanford Neuroscience Health Center- Site Number : 8400120

    Palo Alto, California

  • Private Practice - Dr. Regina Berkovich- Site Number : 8400005

    West Hollywood, California

  • University of Colorado - Anschutz Medical Campus- Site Number : 8400001

    Aurora, Colorado

  • Advanced Neurology of Colorado- Site Number : 8400148

    Fort Collins, Colorado

  • Yale University School of Medicine- Site Number : 8400081

    New Haven, Connecticut

  • Hartford Healthcare Medical Group- Site Number : 8400069

    Norwich, Connecticut

  • MedStar Georgetown University Hospital- Site Number : 8400044

    Washington D.C., District of Columbia

  • Neurology of Central Florida- Site Number : 8400147

    Altamonte Springs, Florida

  • MS & Neuromuscular Center of Excellence- Site Number : 8400015

    Clearwater, Florida

  • Norman Fixel Institute for Neurological Diseases (FIND)- Site Number : 8400054

    Gainesville, Florida

  • Neurology Associates - Maitland- Site Number : 8400010

    Maitland, Florida

  • Orlando Health Neuroscience Institute - Downtown Pavilion- Site Number : 8400060

    Orlando, Florida

  • Axiom Clinical Research of Florida- Site Number : 8400049

    Tampa, Florida

  • University of South Florida- Site Number : 8400013

    Tampa, Florida

  • Palm Beach Neurology- Site Number : 8400105

    West Palm Beach, Florida

  • Joi Life Wellness Group LLC- Site Number : 8400192

    Smyrna, Georgia

  • Rush University Medical Center- Site Number : 8400102

    Chicago, Illinois

  • University of Chicago Medical Center- Site Number : 8400055

    Chicago, Illinois

  • Consultants in Neurology- Site Number : 8400020

    Northbrook, Illinois

  • Neuroscience Institute Center- Site Number : 8400053

    Merrillville, Indiana

  • University of Iowa- Site Number : 8400029

    Iowa City, Iowa

  • University of Kansas Medical Center- Site Number : 8400084

    Kansas City, Kansas

  • Baptist Health Lexington- Site Number : 8400149

    Lexington, Kentucky

  • NeuroMedical Clinic of Central Louisiana- Site Number : 8400159

    Alexandria, Louisiana

  • Ochsner Medical Center - Jefferson Highway- Site Number : 8400027

    New Orleans, Louisiana

  • University of Maryland School of Medicine - Baltimore- Site Number : 8400185

    Baltimore, Maryland

  • Johns Hopkins Hospital- Site Number : 8400080

    Baltimore, Maryland

  • Tufts Medical Center- Site Number : 8400003

    Boston, Massachusetts

  • Boston Clinical Trials- Site Number : 8400178

    Boston, Massachusetts

  • Neurology Center of New England- Site Number : 8400164

    Foxborough, Massachusetts

  • The Elliot Lewis Center- Site Number : 8400033

    Wellesley, Massachusetts

  • UMass Memorial Medical Center - University Campus- Site Number : 8400028

    Worcester, Massachusetts

Showing 40 of 311 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.